Delcath Systems, Inc. (NASDAQ:DCTH) Short Interest Up 13.1% in April

Delcath Systems, Inc. (NASDAQ:DCTHGet Free Report) saw a large increase in short interest during the month of April. As of April 30th, there was short interest totalling 928,700 shares, an increase of 13.1% from the April 15th total of 821,200 shares. Based on an average daily trading volume, of 206,800 shares, the short-interest ratio is currently 4.5 days.

Delcath Systems Stock Performance

Shares of NASDAQ:DCTH opened at $7.07 on Wednesday. Delcath Systems has a 1-year low of $2.25 and a 1-year high of $7.99. The company’s fifty day moving average is $4.89 and its two-hundred day moving average is $4.15. The stock has a market capitalization of $196.40 million, a price-to-earnings ratio of -2.38 and a beta of 0.55.

Delcath Systems (NASDAQ:DCTHGet Free Report) last issued its earnings results on Tuesday, March 26th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.19. The firm had revenue of $0.54 million for the quarter, compared to analysts’ expectations of $0.48 million. Delcath Systems had a negative net margin of 2,308.86% and a negative return on equity of 563.60%. During the same quarter last year, the company posted ($0.86) earnings per share. Sell-side analysts expect that Delcath Systems will post -1.45 EPS for the current fiscal year.

Insider Buying and Selling at Delcath Systems

In other Delcath Systems news, Director Gil Aharon bought 26,882 shares of the company’s stock in a transaction dated Tuesday, March 19th. The shares were acquired at an average cost of $3.72 per share, with a total value of $100,001.04. Following the completion of the transaction, the director now owns 1,069,710 shares in the company, valued at $3,979,321.20. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 17.94% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in DCTH. Vanguard Group Inc. boosted its holdings in shares of Delcath Systems by 31.0% during the first quarter. Vanguard Group Inc. now owns 683,686 shares of the company’s stock valued at $3,261,000 after acquiring an additional 161,678 shares during the period. Vivo Capital LLC grew its position in Delcath Systems by 94.9% in the 1st quarter. Vivo Capital LLC now owns 1,666,746 shares of the company’s stock worth $7,950,000 after purchasing an additional 811,555 shares during the last quarter. ADAR1 Capital Management LLC bought a new position in Delcath Systems in the 4th quarter worth about $962,000. AIGH Capital Management LLC acquired a new stake in shares of Delcath Systems in the fourth quarter valued at approximately $4,918,000. Finally, Worth Venture Partners LLC bought a new stake in shares of Delcath Systems during the fourth quarter valued at approximately $1,224,000. 61.12% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several analysts recently issued reports on DCTH shares. StockNews.com raised shares of Delcath Systems to a “sell” rating in a report on Wednesday, March 27th. Stephens began coverage on shares of Delcath Systems in a research report on Tuesday. They set an “overweight” rating and a $25.00 price target on the stock. Finally, HC Wainwright lifted their price target on Delcath Systems from $18.00 to $20.00 and gave the stock a “buy” rating in a research note on Wednesday, March 27th. One analyst has rated the stock with a sell rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $19.80.

Read Our Latest Report on DCTH

About Delcath Systems

(Get Free Report)

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.

Featured Articles

Receive News & Ratings for Delcath Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Delcath Systems and related companies with MarketBeat.com's FREE daily email newsletter.